Session Details
[S32]Pharmacological approaches to therapeutic target discovery and drug resistance in cancer
Fri. Mar 28, 2025 3:00 PM - 4:30 PM JST
Fri. Mar 28, 2025 6:00 AM - 7:30 AM UTC
Fri. Mar 28, 2025 6:00 AM - 7:30 AM UTC
Room 6 (Fukuoka International Congress Center: 203 [2F])
Organizer: Kazuhiro Katayama (Sch. Pharm., Nihon Univ.), Inoue Yasumichi (Grad. Sch. Pharm. Sci., Nagoya City Univ.)
オーガナイザー挨拶:片山 和浩(日本大薬)
[S32-1]Drug development for Japanese patients using real world data from gene panel testing conducted under national health insurance system
○Takashi Kohno1 (1. Natl Cancer Ctr C-CAT)
[S32-2]Tumor progression by TGF-β signaling inhibitor, TMEPAI: development of novel anti-cancer drugs
○Susumu Itoh1, Naoko Nakano1, Kenya Furudate1, Etsu Tashiro1 (1. Lab. of Biochem. Showa Pharma. Univ.)
[S32-3]Development of targeted protein degraders for cancer therapy
○Nobumichi Ohoka1 (1. NIHS)
[S32-4]Sotorasib function as a pan RAS G12C inhibitor
○Noritaka Tanaka1 (1. Aichi Cancer Center)
[S32-5]Molecular mechanism of stress adaptation inducing proteasome inhibitor non-responsiveness and therapeutic drug development
○Yasumichi Inoue1 (1. Grad. Sch. Pharm. Sci., Nagoya City Univ.)
[S32-6]Molecular mechanisms of resistance to FLT3 inhibitors and development of drugs to overcome the resistance
○Kazuhiro Katayama1 (1. Sch. Pharm., Nihon Univ.)